In this study, we report the cases of two male patients carrying a mtDNA mutation pathogenetic for LHON, both diagnosed with prostate cancer and experiencing late-onset conversion following the introduction of an androgen receptor antagonist (Enzalutamide) to a longstanding hormonotherapy with a GnRH analogue (Leuprolide). This evidence concerns the gene AR and prostate cancer.